EUCTR2013-001697-17-AT进行中（未招募）1 期
PHASE II, MULTICENTRE, OPEN LABEL STUDY TO EVALUATE THE EFFICACY OF THE COMBINATION OF LANREOTIDE AUTOGEL 120 MG AND TEMOZOLOMIDE IN PATIENTS WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURS (GEP-NET) G1/G2 - A PILOT-STUDY - SONNET
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1)Provision of written informed consent prior to any study related procedures.
- •(2)Male or female of 18 years of age or older.
- •(3)Inoperable, Gastro-Entero-Pancreatic-Neuroendocrine Tumour G1 or G2 (Ki67-Index: 0 to =20%) confirmed by pathological/histological assessment.
- •(Previous data assessed not longer than 24 months ago could be used.)
- •(4)Progressive disease within 12 months before inclusion (RECIST 1.1: increase of >20% tumour load; by CT or MRI).
- •(5)Metastatic disease confirmed by CT/MRI.
- •(6)Measureable disease according to RECIST 1.1.
- •(7)Functioning or non-functioning NET (G1, G2).
- •(8)WHO performance status 0-2.
- •(9)Positive Octreo-Scan (= grade 2 Krenning scale) or positive DOTA-TATE/TOC-PET-CT within 12 months prior to screening.
- •(10)Absolute neutrophile count (ANC) = 1,5x10E09/l prior to Temozolomide intake, thrombocyte count = 100 x 10 E09/l prior to Temozolomide intake.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •(1)Has the diagnosis of Insulinoma
- •(2)Has a history of hypersensitivity to Lanreotide or Temozolomide or drugs with a similar chemical structure and/or any known contraindications to magnetic resonance imaging (MRI)/computerised tomography (CT).
- •(3)Was treated with any other IMP within the last 30 days before screening visit.
- •(4)Is likely to require treatment during the study with drugs that are not permitted by the study protocol.
- •(5)Is at risk of pregnancy or lactation. Females of childbearing potential must provide a negative pregnancy test at start of study and must be using oral, double barrier or injectable contraception. Non childbearing potential is defined as post-menopausal for at least 2 years, surgical sterilisation or hysterectomy at least three months before the start of the study (according to CPMP/ICH/286/95, modified).
- •(6)Male patients, who do not agree to use an effective method of contraception if their partner is at risk of becoming pregnant during the course of this study and 6 months after the study drug administration.
- •(7)Male patients who are planning a sperm donation during the entire study participation and at least six months after the last study drug administration.
- •(8)Has any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
- •(9)Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient’s safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.
- •(10)HbA1c > 8,5% (centrally assessed during the screening period).
- •(11)Has had major surgery related to the studied disease within 3 months prior to screening visit.
- •(12)Has a diagnosis of a multiple endocrine neoplasia (MEN).
- •(13)Has received Sunitinib, Everolimus within the last 4 weeks prior to screening visit.
- •(14)Has received PRRT (Peptide Radio-Receptor-Therapy) within 3 months prior to screening visit.
- •(15)Has received prior chemotherapy regimens within 4 weeks prior to screening visit.
- •(16)Has received any Temozolomide treatment prior to screening visit.
- •(17)Has undergone radiation of target lesions within 12 months prior to screening visit.
- •(18)Has received Interferon-a treatment within 4 weeks prior to screening visit.
- •(19)Has received local ablative therapies (TACE, SIRT, RFA) within 6 months prior to screening visit.
- •(20)Has had a previous cancer (except basocellular carcinoma of the skin and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for more than 5 years) other than study indication.
- •(21)Has a history of, or known current, problems with alcohol or drug abuse.
- •(22)Is deprived of his/her freedom or rights by virtue of an order issued either by any judicial or administrative authorities, is unable to express his/her consent, or is committed to a social or health institution for reasons other than the study.
- •(23)Has been previously enrolled in this study.
- •(24)Participation in other trials for the duration of this trial.
- •(25)Hypersensitivity to dacarbazine (DTIC).
研究者
相似试验
进行中（未招募）
1 期
Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURSmetastatic functioning and non-functioning entero-pancreatic tumoursEUCTR2013-001697-17-DEIpsen Pharma GmbH65
进行中（未招募）
不适用
MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA - PERCATPERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMAMedDRA version: 12.1Level: LLTClassification code 10068069Term: Peritoneal carcinomatosisMedDRA version: 12.1Level: LLTClassification code 10052360Term: Colorectal adenocarcinomaMedDRA version: 12.1Level: LLTClassification code 10017758Term: Gastric cancerEUCTR2010-022810-26-DEniversity Witten/Herdecke40
进行中（未招募）
1 期
Study of U3-1402 in subjects with colorectal cancerAdvanced or metastatic colorectal cancer (CRC) which is resistant, refractory, or intolerant to at least 2 prior lines of therapy, that must include all of the following agents: fluoropyrimidine, irinotecan, platinum agent, an anti-epidermal growth factor receptor (EGFR) agent (if clinically indicated) and, unless contraindicated, an anti- vascular endothelial growth factor (VEGF) agent.MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2019-004418-32-ITDAIICHI SANKYO INC.80
已完成
2 期
A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3- 1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)Metastatic Colorectal CancerJPRN-jRCT2031200139Inoguchi Akihiro80
进行中（未招募）
1 期
Study of U3-1402 in subjects with colorectal cancerEUCTR2019-004418-32-PLDAIICHI SANKYO, INC80